{"name":"Telix Pharmaceuticals (Innovations) Pty Limited","slug":"telix-pharmaceuticals-innovations-pty-limited","ticker":"","exchange":"","domain":"telixinnovationspty.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","indication":"Prostate cancer","status":"phase_1"},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","indication":"Prostate cancer","status":"phase_1"},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","indication":"Neuroendocrine tumors","status":"phase_1"}]}],"pipeline":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","phase":"phase_1","mechanism":"A radioligand targeting somatostatin receptors","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","phase":"phase_1","mechanism":"Iodine-131 labelled peptide for targeted radionuclide therapy","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","phase":"phase_2","mechanism":"177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","phase":"phase_3","mechanism":"177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","phase":"phase_1","mechanism":"Somatostatin receptor targeting","indications":["Neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNZDR2cnF2QllxeWg3SFpRRlAzZWo3WHlrNUN1UXJyQlJFQUwxVVlHeEJzQTVvc2ZJUUdCTEtfZ1pjd0JyMlZVT3J1dW1EeTZoOVZHTHdFT1lwUEJqVDRfTnUzSVdoVW5GUl80QmNhVWFmNk5WQVctS2RUeWc0MVVUaUswYmFBemd6WnNiTEE3Y3IwWGxVSkV1T240MFJPOUxfRFo1TXZiZllMLUZUZGIwYTI4NlY?oc=5","date":"2026-02-20","type":"pipeline","source":"kalkinemedia.com","summary":"Telix Pharmaceuticals Advances Within ASX 200 After Strong FY Update - kalkinemedia.com","headline":"Telix Pharmaceuticals Advances Within ASX 200 After Strong FY Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOM0swbmNtelNfUE9HTnVscF9xNmFsTUlqNC0yMVloWUJUc1ZENUNGYXpZeHBJX3RTejFHSHNuZVhPNlo1Wi1BRmprLWhmTDJ6TjdCaFdBQzY0RzVnUW5WSVZJZ2xMc28zNHpxU2tLQlZtcW4tNUVPTzc3R0QxMlBocWNHTHVEaC1YQmI3cDY3YXZoMU9EcFcxN0ROWXhNWVVjbGVHZFlMaXdZVm44aldyMnJ2bkRTaEJwelE?oc=5","date":"2026-01-27","type":"pipeline","source":"kalkinemedia.com","summary":"Telix Pharmaceuticals across ASX 200 and All Ordinaries healthcare space - kalkinemedia.com","headline":"Telix Pharmaceuticals across ASX 200 and All Ordinaries healthcare space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZWFyaGZIdjZ2QzkwM2VoeTh3ZmxZMWxpU05LaEh2bWRkTzdWbFdSYjJoTzVKSEw2d2VlYmQ0b0J0X2x0MHRnVWZVN3NmM3ZxWUNybV9NUFNJUS11d2otc1FaWERnQmlRbFNLQ0VzWUptOTFTZEY3OUNmcEJic2QtUnZCZUZyQ2FwcGJSY0ZkSERHZDhXMzFrX0JieUt2NDh5QXVLSG5iaWlkZzA?oc=5","date":"2026-01-19","type":"pipeline","source":"kalkinemedia.com","summary":"Telix Pharma (ASX:TLX) Shares Fluctuate With ASX 200 Index Today - kalkinemedia.com","headline":"Telix Pharma (ASX:TLX) Shares Fluctuate With ASX 200 Index Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNbEdhSXJ4ejU4aGJlMFVLcWV5V0tpeTBiQVgxc3FmeFJkTzRGczRvNzdySXNPSGpFMGxBT3ZSZlB6MXctdTBycTQ4UGJXT1lFYm5DVjk2ZlpzNFpQTnN3aWRUZmZOZUZJSTNQR1NPN2dFRDM3UlBOcGtDSTRLWnhnNXFLZHktdHRVTUpRRHEtS05YMlRhRFo5OW9rdTVRZFFFRTNIVkZTZ2lhSU5JamxzTXJManlLV1B2VUh1Z3B5ZkZuQWlyOERUQ1B6U0w1Ym1MMVZaTXZRSFpEeDNIQm9FTVhfNFZPWDQ0b3FhS2JtZGJpYTlJaFZVMdIB_gFBVV95cUxNcTJqX25OaFFkM1ZsZmw1azlGMms3YUY2SHlIM3lKRVl0N3hmVUQtUkpta1QzYk5oQXMzYTJYMjRVYmI3VnRFd05vZTFCQTN0WENQV3ByOF9oLThkMnJOMnItSnBGMmZ6Nm12ZXN1VVVqRHJyN0J1QnlKMjkwR2lHMGhoUlh1c3NJd1lRVUFZSjlpZTBOUFl4WWwtNEE3bXFfbXZTbWZjdUQ1T1BzZUtrRXJ5amhDQkllY05CTUxPYTgyNFJVR0sxcHlTMjR6RjhUUURaTndZRTh6S0gtZkhwQ3UxQVJtTEstZjlSUnluMEpRUWRoNzZFUzhFNEpqUQ?oc=5","date":"2025-12-05","type":"pipeline","source":"Herald Sun","summary":"Everybody appearing in Victoria Supreme Court matters on Friday, December 5 - Herald Sun","headline":"Everybody appearing in Victoria Supreme Court matters on Friday, December 5","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQdndISjlmUWptZkhTekoyQVd3UWwzSUdWUW85Qkp5Q2FTM0cwTlJ6RUJYel9OOXVjQWFNZjdqNXIzRDRMd0d2Y0JmcWhNcXpSaGFpX3J4d0IzYy1rVWlQSTU5Rm13VHhkdndmWHFUd0Z1enZnTGpJUExaSXhtOFUzUEZOM0NkZFVudnVkNVRiOHZRa3gwVHdXV19OdzcyN05EM3I5ZXdVUC11WDFlN3VUNVdhLTBNVXlmM0E?oc=5","date":"2025-09-26","type":"pipeline","source":"AFR","summary":"CSL, Telix and other pharma groups rush to calm investor fears over Donald Trump’s tariff hit - AFR","headline":"CSL, Telix and other pharma groups rush to calm investor fears over Donald Trump’s tariff hit","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-09","type":"pipeline","source":"Sky News Australia","summary":"ASX sinks while Australian pharmaceutical company soars - Sky News Australia","headline":"ASX sinks while Australian pharmaceutical company soars","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR0twSHktVk9leUVGV0wyVHBycDh6VjFabXRJQnhQSkNzamJOWjBoSFVmSHltYUpTcXV0dXJ6TEhtVFNhdlNIMGwwYlBmbFFtT1FBX1lkV1VuTWVqQ3ZXMjZKaXJ3V1Y0TXdwMk5kWU0ya0Z3RlNPTUN2MVN4akVSRVgyTFBPdERVN0tBc3B3Wk52MEx1aGZvTU9tVVNOanBwZUtjNDFmVXJ4OG1uT1R4bnd3djFERXB2WVdZ?oc=5","date":"2025-05-26","type":"pipeline","source":"Forbes Australia","summary":"Australian startups take on big pharma with precision cancer breakthroughs - Forbes Australia","headline":"Australian startups take on big pharma with precision cancer breakthroughs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNcGhTMXcxMEpOc0lDeXlBUzVUdWd3eGpaNlM1N0tzR0lmN0duRmJPYjM4V3JBZmFFcGl2eFJhLVF5VHNXTmplQ19IcjlmRjloQTNJNGJOb2pjamVlcUtpWHViRjdEYXhGd3ZqTl9aX3hPVy1DMVJ1X2IzQk5HQkNqTW1vSmd6WmoxRW1aUE9YZVNXMXIydXhzejhDY3NZM0VtMWhSdWxsN19TTkNJQWdaNW5oN2M5RXhDYnJWWm5BRXdGUFFoUkpqWF9Lb1BrUzNteW5NSGpVMzBSSWtxalFCT0VVRTBaQQ?oc=5","date":"2025-01-13","type":"deal","source":"Radiology Business","summary":"Telix Pharmaceuticals to acquire portfolio of imaging-related assets for up to $185M - Radiology Business","headline":"Telix Pharmaceuticals to acquire portfolio of imaging-related assets for up to $185M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxQNURjWXBVd2hheWNTV0c1VG1SNldsdFB4NzFjTnBFeDg2TEY0TWRIdmdrcG1RQmhPdzM1OUp5YlY0Uy1kaGxFdFNUelV5dURXcVVzRkl5aE5JQXFIU1hETHpEdjZrYWpWel9vdjBHUF9DVmMyblR5RlpCcnQwU3hKRkNRaktNTk1nSkUzeFdxMW41VVJYbU13ZUw4SlhLREU3RVozTnlJakxnc2QxZUhfM0hmUG1sLXhXbGFoUkdWVkpxbm5YOFVxdEFOd0N0Y25NQ3dBVldabk1CbTdTQ183T3V6R0lERHkzOW9Tc0JnZGVvMkxZSVZQbU9wRXFzLThR?oc=5","date":"2025-01-13","type":"deal","source":"BioPharma APAC","summary":"Telix Pharmaceuticals Acquires ImaginAb’s Biologics Platform and Therapeutics Pipeline to Advance Precision Radiopharmaceuticals - BioPharma APAC","headline":"Telix Pharmaceuticals Acquires ImaginAb’s Biologics Platform and Therapeutics Pipeline to Advance Precision Radiopharmac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQUDR3WkZSaFUteVRZOXdNSHpfX1F5ZDRucHFUY3hpU1l5dDBqcnJ4MExwOEtUSkNVV1J4TEwyVl9qa3ZDRGFnWEc3Q3Vtakk1dFkyUU5zakhNR05xUGxFQ2FQeXA2Q1hkVXJIMHpaeDExb3BFazhqbldrbzJtWWk1Q2J4UXpMeHh5aHZSM2hOX252TTEtcjJER2M5MDIxd3RGa1dCYW9XV0hBS1k5NkNrZ2x2d0NZM0p6MGtPRkRFb215ZlVENGxKR3hKc3BKZXI4ZGZqcG9UbEgyR1I4Nzh2SE1ycDJpOFE?oc=5","date":"2025-01-12","type":"deal","source":"prnewswire.com","summary":"Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - prnewswire.com","headline":"Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPVVdhNnBjNjBBeUNvMWhjRUNJLXFSZUxNTWt0MV9hTFoyN1hBSTRLQmxSc2ZjWGJqTW5jTHIzQ08wNzVLT0tsYnpjSGRreTBnWGM2Mm5tcGJKS3RBTFZSZkVBMTM5dDZfX293UU9sS0Y2MF8wNTFPRW5oNWVnY21nSzQ4bDdZbk5YTW02M2RWUUpfLUQ0Y0Z3NDF3NUFSYXhiSTN4bkMtSkpOX214M3RfSGlOdWpHa3hkbldtdWRQcnBBQl80RWsybFF6NjNtSHhjcUJZYzl3QU4yUmFmVzFhelhn?oc=5","date":"2024-10-22","type":"pipeline","source":"GlobeNewswire","summary":"Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals - GlobeNewswire","headline":"Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":3,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}